| Hans-Günter Meyer-Thompson | Naltrexon
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Kosten T, Aharonovich E, Nangia N, et al.
Addict Behav. 2020;111:106538. doi:10.1016/j.addbeh.2020.106538
https://www.sciencedirect.com/science/article/pii/S0306460320306687